Table 3.
Group of Antideoressants | Medication | Study | Duration of the Study (Weeks) | Patient Group (n) | Effect * |
---|---|---|---|---|---|
BDNF | |||||
SSRI | Sertraline | Wolkowitz et al. [21] | 8 | n = 10 | ↑ |
Brunoni et al. [19] | 6 | n = 18 | ↓ | ||
Umene-Nakano et al. [58] | 8 | n = 59 | ↑ (responders only) | ||
Matrisciano et al. [54] | 6 months | n = 7 | ↑ | ||
Gonul et al. [59] | 8 | n = 8 | ↑ | ||
Escitalopram | Wolkowitz et al. [21] | 8 | n = 15 | ↑ | |
Matrisciano et al. [54] | 6 months | n = 7 | ↑ | ||
Aydemir et al. [60] | 6 | n = 20 | ↑ | ||
Chiou et al. [39] | 4 | n = 2 | ↓ | ||
Paroxetine | Yoshimura et al. [61] | 8 | n = 21 | ↑ | |
Gonul et al. [59] | 8 | n = 3 | ↑ | ||
Chiou et al. [39] | 4 | n = 7 | ↓ | ||
Hellweg et al. [56] | 36 days | n = 20 | ↓ | ||
Fluoxetine | Başterzi et al. [55] | 6 | n = 22 | ↑/↓ | |
Gupta et al. [40] | 12 | n = 30 | ↑ | ||
Gonul et al. [59] | 8 | n = 5 | ↑ | ||
Ghosh et al. [62] | 12 | n = 30 | ↑ | ||
Chiou et al. [39] | 44 | n = 21 | ↓ | ||
SNRI | Vortixetine | Troyan et al. [41] | 8 | n = 30 | ↑ |
Sagud et al. [42] | 4 | n = 44 | ↑ | ||
Venlafaxine | Başterzi et al. [55] | 6 | n = 21 | ↓ | |
Matrisciano et al. [54] | 6 months | n = 7 | ↑ (after 6 months of treatment) | ||
Katsuki et al. [63] | 4 | n = 48 | ↑ | ||
Gonul et al. [59] | 8 | n = 10 | ↑ | ||
Chiou et al. [39] | 4 | n = 8 | ↓ | ||
Deuschle et al. (2012) [64] | 28 days | n = 27 | ↔ | ||
Duloxetine | Mikoteit et al. [65] | 6 | n = 21 | ↑ | |
Other | Mirtazapine | Fornaro et al. [66] | 12 | n = 30 | ↑ early non-responders, ↔ early responders |
Deuschle et al. (2012) [64] | 28 days | n = 29 | ↑ | ||
Chiou et al. [39] | 4 | n = 3 | ↓ | ||
Ketamine | Zheng et al. [43] | 26 days | n = 94 | ↑ | |
Milnacipran | Yoshimura et al. [61] | 8 | n = 21 | ↑ | |
Amitryptyline | Hellweg et al. [56] | 36 days | n = 20 | ↑ | |
IGF-1 | |||||
SSRI | N/A | Kopczak et al. [46] | 6 | n = 13 | ↓ |
Fluoxetine Citalopram Paroxetine Sertraline Fluvoxamine |
Bot et al. [44] | N/A |
n = 52 n= 96 n = 195 n = 40 n = 38 |
↓ ↓ ↓ ↓ ↓ |
|
SNRI | N/A | Kopczak et al. [46] | 6 | n = 12 | ↓ |
Vortioxetine | Troyan et al. [41] | 8 | n = 41 | ↓ | |
Levada et al. [45] | 8 | n = 48 | ↓ | ||
Venlafaxine | Bot et al. [44] | N/A | n = 95 | ↓ | |
TCA | Clomipramine Amitriptyline |
Bot et al. [44] | N/A |
n = 26 n = 21 |
↓ ↓ (not statistically significant) |
N/A | Kopczak et al. [46] | 6 | n = 14 | ↓ | |
Other | Mirtazapine | Kopczak et al. [46] | 6 | n = 8 | ↓ |
Bot et al. [44] | N/A | n = 33 | ↓ (not statistically significant) |
* ↑ increase, ↓ decrease, unchanged.